Latest News-CSTONE PHARMACEUTICALS Mediaroom_Page

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2020-01-24 14:26 3142

CStone successfully hosted the first U.S. R&D Day in New York

* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical de...

2020-01-24 08:18 3560

CStone successfully hosted the first U.S. R&D Day in New York

* Among CStone's 15 cancer drug candidates, five candidates are in pivotal late-stage clinical de...

2020-01-24 08:03 2373

CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma

SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX...

2020-01-08 13:45 2688

CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia

SUZHOU, China, Dec. 12, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-12-12 14:47 2596

CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST

SUZHOU, China, Dec. 11, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-12-11 11:00 2540

CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-12-10 11:38 2295

CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial

SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX...

2019-12-06 18:53 3116

CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib

SUZHOU, China, Nov. 20, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-11-20 11:41 1949

ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

SUZHOU, China, Nov. 7, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX...

2019-11-07 11:02 1849

ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability

SUZHOU, China, Sept. 30, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-09-30 18:29 2009

2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors

SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-09-22 14:22 1589

2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab

SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-09-22 13:39 1780

2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors

SUZHOU, China, Sept. 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-09-21 00:26 1850

2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%

SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-09-19 23:48 1963

CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST

SUZHOU, China, Aug. 26, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today an...

2019-08-26 11:21 2843

CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting

SUZHOU, China, Aug. 23, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKE...

2019-08-23 11:26 3249

CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study

SUZHOU, China, Aug. 23, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HK...

2019-08-23 11:20 2570

CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting

SUZHOU, China, Aug. 20, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today an...

2019-08-20 10:18 5938

Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress

SUZHOU, China, Aug. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today an...

2019-08-19 13:50 6086